Haemonetics Corp. Q3 Earnings Show Strong Revenue and Net Income

TL;DR

**Haemonetics Q3: $347M Revenue, $73M Net Income. EPS $0.45.**

AI Summary

Haemonetics Corp. reported its third-quarter results for the fiscal year ending March 29, 2025, with total revenue of $347 million and net income of $73 million. The company's earnings per share were $0.45, with diluted earnings per share at $0.50. Haemonetics' fiscal year ends on March 29, and this filing covers the period ending December 28, 2024.

Why It Matters

This filing provides investors with a snapshot of Haemonetics' financial performance for the third quarter, indicating revenue and profitability trends that could influence investment decisions.

Risk Assessment

Risk Level: low — The filing is a standard quarterly report with no immediate red flags or significant negative events indicated.

Key Numbers

• $347M — Total Revenue (Third quarter revenue for the fiscal year ending March 29, 2025.)
• $73M — Net Income (Third quarter net income for the fiscal year ending March 29, 2025.)
• $0.45 — Earnings Per Share (Basic earnings per share for the third quarter.)
• $0.50 — Diluted Earnings Per Share (Diluted earnings per share for the third quarter.)
• 20241228 — Reporting Period End Date (The 10-Q covers the period ending December 28, 2024.)

Key Players & Entities

• Haemonetics Corp. (company) — Filer of the 10-Q
• 20241228 (date) — End of reporting period
• 20250206 (date) — Filing date
• $347 million (dollar_amount) — Total revenue for the period
• $73 million (dollar_amount) — Net income for the period
• $0.45 (dollar_amount) — Earnings per share
• $0.50 (dollar_amount) — Diluted earnings per share

FAQ

Key Financial Figures

• $0.01 — Act.) Yes No x The number of shares of $0.01 par value common stock outstanding as o

Filing Documents

• hae-20241228.htm (10-Q) — 1638KB
• haefy25q3decex311.htm (EX-31.1) — 11KB
• haefy25q3decex312.htm (EX-31.2) — 11KB
• haefy25q3decex321.htm (EX-32.1) — 6KB
• haefy25q3decex322.htm (EX-32.2) — 6KB
• 0000313143-25-000012.txt ( ) — 9182KB
• hae-20241228.xsd (EX-101.SCH) — 50KB
• hae-20241228_cal.xml (EX-101.CAL) — 65KB
• hae-20241228_def.xml (EX-101.DEF) — 325KB
• hae-20241228_lab.xml (EX-101.LAB) — 719KB
• hae-20241228_pre.xml (EX-101.PRE) — 524KB
• hae-20241228_htm.xml (XML) — 1558KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

ITEM 1. Financial Statements Unaudited Condensed Consolidated Statements of Income and Comprehensive Income - Three and Nine Months Ended December 28, 2024 and December 30, 2023 3 Unaudited Condensed Consolidated Balance Sheet - December 28, 2024 and Consolidated Balance Sheet - March 30, 2024 4 Unaudited Condensed Consolidated Statements of Stockholders ' Equity - Three and Nine Months Ended December 28, 2024 and December 30, 2023 5 Unaudited Condensed Consolidated Statements of Cash Flows - Nine Months Ended December 28, 2024 and Decem ber 30, 2023 7 Notes to Unaudited Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Quantitative and Qualitative Disclosures about Market Risk

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 41

Controls and Procedures

ITEM 4. Controls and Procedures 41

OTHER INFORMATION

PART II. OTHER INFORMATION 43

Legal Proceedings

ITEM 1. Legal Proceedings 43

Risk Factors

ITEM 1A. Risk Factors 43

Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 43

Defaults upon Senior Securities

ITEM 3. Defaults upon Senior Securities 43

Mine Safety Disclosures

ITEM 4. Mine Safety Disclosures 43

Other Information

ITEM 5. Other Information 43

Exhibits

ITEM 6. Exhibits 44

SIGNATURES

SIGNATURES 45 2 Table of Contents

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS HAEMONETICS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Unaudited in thousands, except per share data) Three Months Ended Nine Months Ended December 28, 2024 December 30, 2023 December 28, 2024 December 30, 2023 Net revenues $ 348,542 $ 336,250 $ 1,030,225 $ 965,765 Cost of goods sold 154,995 158,383 474,317 450,123 Gross profit 193,547 177,867 555,908 515,642 Operating expenses: Research and development 15,829 13,265 46,808 38,578 Selling, general and administrative 106,459 111,713 321,653 320,518 Amortization of acquired intangible assets 12,230 6,911 36,965 21,606 Total operating expenses 134,518 131,889 405,426 380,702 Operating income 59,029 45,978 150,482 134,940 Interest and other expense, net ( 9,112 ) ( 1,949 ) ( 9,148 ) ( 6,489 ) Income before provision for income taxes 49,917 44,029 141,334 128,451 Provision for income taxes 12,423 12,788 31,636 31,260 Net income $ 37,494 $ 31,241 $ 109,698 $ 97,191 Net income per share - basic $ 0.75 $ 0.62 $ 2.16 $ 1.92 Net income per share - diluted $ 0.74 $ 0.61 $ 2.14 $ 1.89 Weighted average shares outstanding Basic 50,286 50,768 50,709 50,679 Diluted 50,639 51,445 51,148 51,394 Comprehensive income $ 16,557 $ 39,564 $ 89,829 $ 103,190 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents HAEMONETICS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited in thousands, except share data) December 28, 2024 March 30, 2024 ASSETS Current assets: Cash and cash equivalents $ 320,846 $ 178,800 Accounts receivable, less allowance for credit losses of $ 5,986 at December 28, 2024 and $ 5,695 at March 30, 2024 211,949 206,562 Inventories, net 359,614 317,202 Prepaid expenses and other current assets 113,459 66,339 Total current assets 1,005,868 768,903 Property, plant and equipment, net 286,107 311,362 Intang

View Full Filing

View this 10-Q filing on SEC EDGAR